4.6 Review

Hangeshashinto for preventing oral mucositis in patients receiving cancer treatment: protocol for a systematic review and meta-analysis

Journal

BMJ OPEN
Volume 11, Issue 5, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/bmjopen-2020-047627

Keywords

complementary medicine; herbal medicine; radiation oncology; chemotherapy

Funding

  1. National Administration of Traditional Chinese Medicine (TCM): 2019 project of building evidence based practice capacity for TCM [2019XZZX-ZL006]
  2. National Natural Science Foundation of China [81774284]
  3. Project of Science and Technology Department of Sichuan Province [2020098]
  4. Provincial Developmental Fund of TCM--Key Discipline of TCM (Oncology of TCM) [2100601]

Ask authors/readers for more resources

This study aims to evaluate the effectiveness of Hangeshashinto in preventing oral mucositis in cancer patients receiving treatment. The study will include literature search, risk of bias assessment, and outcomes evaluation such as incidence of mucositis, interruptions to cancer treatment, oral pain, and nutritional status. The findings will provide valuable information for clinical decision-making in this area.
Introduction Hangeshashinto has been employed for oral mucositis prevention in patients receiving cancer treatment, but the evidence has not been sufficiently robust to guide clinical decision-making. This study will therefore be undertaken to assess the effectiveness of Hangeshashinto for preventing oral mucositis in patients with cancer who are receiving treatment. Methods and analysis The databases will include PubMed, Embase, the Cochrane Library, Chinese databases and Japanese databases. The literature will be searched from the databases' inception until May 2021. Other sources, such as potential grey literature, reference lists from included studies and relevant systematic reviews and conference papers, will also be searched. The primary outcome is the incidence of mucositis of any severity, and the secondary outcomes are interruptions to cancer treatment, oral pain and nutritional status. The risk of bias of eligible studies will be assessed using the Cochrane Collaboration's 'risk of bias' tool. Both the Q test and I-2 statistic will be performed to assess statistical heterogeneity. If I-2 >50%, sensitivity and subgroup analysis will be conducted. The quality of evidence will be rated according to the Grading of Recommendations, Assessment, Development and Evaluation approach. Egger's test will be used to assess reporting bias. Ethics and dissemination This systematic review will evaluate only published data; therefore, ethical approval is not required. PROSPERO registration number CRD42020216145.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available